On Wednesday, NCPA CEO Douglas Hoey participated in a Health Care Working Group convened by Sen. Rick Scott (R-Fla.). NCPA was one of several players in the drug supply chain invited to participate, including other pharmacies, insurers, PBMs, manufacturers, and other health care stakeholders, as well as additional senators and their staffs. Hoey shared community pharmacy priorities for lowering drug costs and improving transparency. He also stressed that the top regulatory policy with the potential to lower drug costs would be CMS's proposed rule to reform DIR fees. NCPA thanks Sen. Scott for the invitation, and we look forward to working with him, his staff, and other members of Congress on a permanent legislative solution on drug pricing and transparency.
NCPA
